Baxter International (NYSE:BAX) Price Target Cut to $30.00 by Analysts at Barclays

Baxter International (NYSE:BAX) had its price objective lowered by investment analysts at Barclays from $36.00 to $30.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the medical instruments supplier’s stock. Barclays‘s price objective indicates a potential upside of 44.75% from the company’s current price.

Other analysts also recently issued reports about the company. Citigroup dropped their price objective on Baxter International from $26.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, October 31st. Weiss Ratings reissued a “sell (d)” rating on shares of Baxter International in a research report on Wednesday, October 8th. Cowen restated a “hold” rating on shares of Baxter International in a research note on Thursday, October 30th. JPMorgan Chase & Co. cut their price objective on Baxter International from $25.00 to $19.00 in a report on Friday, October 31st. Finally, Morgan Stanley decreased their target price on Baxter International from $19.00 to $15.00 and set an “underweight” rating for the company in a report on Tuesday, December 2nd. Two research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $21.30.

Baxter International Trading Up 0.2%

Shares of BAX traded up $0.04 during mid-day trading on Friday, hitting $20.73. The company had a trading volume of 1,764,475 shares, compared to its average volume of 8,857,053. The business’s 50-day simple moving average is $18.78 and its 200-day simple moving average is $22.92. The company has a quick ratio of 1.18, a current ratio of 1.84 and a debt-to-equity ratio of 1.21. Baxter International has a 1-year low of $17.40 and a 1-year high of $37.74. The stock has a market cap of $10.65 billion, a PE ratio of -31.45, a P/E/G ratio of 1.19 and a beta of 0.59.

Baxter International (NYSE:BAX) last issued its quarterly earnings results on Thursday, October 30th. The medical instruments supplier reported $0.69 EPS for the quarter, topping the consensus estimate of $0.60 by $0.09. The firm had revenue of $2.84 billion during the quarter, compared to analyst estimates of $2.88 billion. Baxter International had a negative net margin of 3.09% and a positive return on equity of 17.38%. Baxter International’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.80 earnings per share. Baxter International has set its Q4 2025 guidance at 0.520-0.570 EPS and its FY 2025 guidance at 2.350-2.400 EPS. Sell-side analysts forecast that Baxter International will post 2.48 earnings per share for the current year.

Institutional Trading of Baxter International

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Creative Financial Designs Inc. ADV lifted its stake in shares of Baxter International by 169.6% in the second quarter. Creative Financial Designs Inc. ADV now owns 984 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 619 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in Baxter International by 14.4% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 5,448 shares of the medical instruments supplier’s stock worth $124,000 after purchasing an additional 686 shares during the last quarter. MassMutual Private Wealth & Trust FSB raised its position in shares of Baxter International by 40.1% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 2,831 shares of the medical instruments supplier’s stock valued at $86,000 after purchasing an additional 810 shares in the last quarter. CoreFirst Bank & Trust purchased a new position in shares of Baxter International during the 2nd quarter valued at approximately $27,000. Finally, Public Employees Retirement System of Ohio grew its position in shares of Baxter International by 0.6% during the third quarter. Public Employees Retirement System of Ohio now owns 160,033 shares of the medical instruments supplier’s stock worth $3,644,000 after buying an additional 993 shares in the last quarter. 90.19% of the stock is owned by hedge funds and other institutional investors.

About Baxter International

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.